Revista medica de Chile · 2026
Chilean Multidisciplinary Consensus on the Use of GLP-1 Receptor Agonists: Recommendations Based on the GRADE Methodology.
Consensus StatementСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cabrera Sebastián, Walbaum Magdalena, Bórquez Tamara, Fuentes Catalina, Acevedo Mónica, Varleta Paola, Belmar Pamela, Gómez Patricia, Sanzana María Gabriela, Vega Javier, Navarro Gustavo, Saavedra Carla, Hernández Mario, Gómez Sabrina, Lorca Eduardo
Аннотация
UNLABELLED: Type 2 diabetes (T2DM), obesity, chronic kidney disease (CKD), and heart failure (HF) pose a major public health burden in Chile and Latin America. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide glycemic, cardiovascular, renal, and weight-loss benefits, extending their therapeutic role beyond glycemic control.
AIM: To develop a national consensus, based on GRADE methodology, that synthesizes the best available evidence and adapts it to the Chilean healthcare context, providing practical recommendations for the rational use of GLP-1 RA (GLP-1 receptor agonists).
METHODS: A multidisciplinary panel convened by six Chilean scientific societies developed this consensus, using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. A systematic review of randomized trials and meta-analyses was conducted. Evidence tables were prepared and critically appraised to support transparent recommendations adapted to the Chilean healthcare context.
RESULTS: The panel formulated seven key recommendations: (1) a strong recommendation for GLP-1 RAs in patients with T2DM and CKD; (2) a weak recommendation in CKD without diabetes; (3) a strong recommendation in T2DM with high cardiovascular risk; (4) a weak recommendation over sulfonylureas as add-on to metformin; (5) a strong recommendation in HF with preserved ejection fraction (HFpEF) and BMI ≥27; (6) a strong recommendation in obesity with T2DM; and (7) a weak recommendation in obesity without T2DM.
CONCLUSIONS: This consensus synthesizes international evidence and contextualizes it to Chile, supporting rational, equitable, and transparent implementation of GLP-1 RAs. These agents are positioned as central tools in the management of the cardiorenal-metabolic syndrome, complementing current cost-effective therapies and lifestyle interventions.
AIM: To develop a national consensus, based on GRADE methodology, that synthesizes the best available evidence and adapts it to the Chilean healthcare context, providing practical recommendations for the rational use of GLP-1 RA (GLP-1 receptor agonists).
METHODS: A multidisciplinary panel convened by six Chilean scientific societies developed this consensus, using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. A systematic review of randomized trials and meta-analyses was conducted. Evidence tables were prepared and critically appraised to support transparent recommendations adapted to the Chilean healthcare context.
RESULTS: The panel formulated seven key recommendations: (1) a strong recommendation for GLP-1 RAs in patients with T2DM and CKD; (2) a weak recommendation in CKD without diabetes; (3) a strong recommendation in T2DM with high cardiovascular risk; (4) a weak recommendation over sulfonylureas as add-on to metformin; (5) a strong recommendation in HF with preserved ejection fraction (HFpEF) and BMI ≥27; (6) a strong recommendation in obesity with T2DM; and (7) a weak recommendation in obesity without T2DM.
CONCLUSIONS: This consensus synthesizes international evidence and contextualizes it to Chile, supporting rational, equitable, and transparent implementation of GLP-1 RAs. These agents are positioned as central tools in the management of the cardiorenal-metabolic syndrome, complementing current cost-effective therapies and lifestyle interventions.